메뉴 건너뛰기




Volumn 10, Issue 9, 2011, Pages 806-818

FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: A diagnostic study

(25)  Suomalainen, Anu a,b   Elo, Jenni M a   Pietiläinen, Kirsi H a   Hakonen, Anna H a   Sevastianova, Ksenia a   Korpela, Mari b   Isohanni, Pirjo a,b   Marjavaara, Sanna K a   Tyni, Tiina a,b   Kiuru Enari, Sari b   Pihko, Helena b   Darin, Niklas a   Õunap, Katrin d   Kluijtmans, Leo A J e   Paetau, Anders b   Buzkova, Jana a   Bindoff, Laurence A a   Annunen Rasila, Johanna c   Uusimaa, Johanna c   Rissanen, Aila a   more..


Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; FIBROBLAST GROWTH FACTOR 21; LACTIC ACID; PYRUVIC ACID;

EID: 80051667626     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70155-7     Document Type: Article
Times cited : (349)

References (33)
  • 2
    • 39049156470 scopus 로고    scopus 로고
    • Prevalence of mitochondrial DNA disease in adults
    • Schaefer AM, McFarland R, Blakely EL, et al. Prevalence of mitochondrial DNA disease in adults. Ann Neurol 2008, 63:35-39.
    • (2008) Ann Neurol , vol.63 , pp. 35-39
    • Schaefer, A.M.1    McFarland, R.2    Blakely, E.L.3
  • 3
    • 0042266280 scopus 로고    scopus 로고
    • Minimum birth prevalence of mitochondrial respiratory chain disorders in children
    • Skladal D, Halliday J, Thorburn DR Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain 2003, 126:1905-1912.
    • (2003) Brain , vol.126 , pp. 1905-1912
    • Skladal, D.1    Halliday, J.2    Thorburn, D.R.3
  • 4
    • 67349120136 scopus 로고    scopus 로고
    • Multisystem manifestations of mitochondrial disorders
    • Di Donato S Multisystem manifestations of mitochondrial disorders. J Neurol 2009, 256:693-710.
    • (2009) J Neurol , vol.256 , pp. 693-710
    • Di Donato, S.1
  • 5
    • 33645052713 scopus 로고    scopus 로고
    • Mitochondrial medicine: a metabolic perspective on the pathology of oxidative phosphorylation disorders
    • Smeitink JA, Zeviani M, Turnbull DM, Jacobs HT Mitochondrial medicine: a metabolic perspective on the pathology of oxidative phosphorylation disorders. Cell Metab 2006, 3:9-13.
    • (2006) Cell Metab , vol.3 , pp. 9-13
    • Smeitink, J.A.1    Zeviani, M.2    Turnbull, D.M.3    Jacobs, H.T.4
  • 6
    • 70450206923 scopus 로고    scopus 로고
    • EFNS guidelines on the molecular diagnosis of mitochondrial disorders
    • Finsterer J, Harbo HF, Baets J, et al. EFNS guidelines on the molecular diagnosis of mitochondrial disorders. Eur J Neurol 2009, 16:1255-1264.
    • (2009) Eur J Neurol , vol.16 , pp. 1255-1264
    • Finsterer, J.1    Harbo, H.F.2    Baets, J.3
  • 7
    • 79955701172 scopus 로고    scopus 로고
    • Biomarkers for mitochondrial respiratory chain disorders
    • Suomalainen A Biomarkers for mitochondrial respiratory chain disorders. J Inherit Metab Dis 2011, 34:277-282.
    • (2011) J Inherit Metab Dis , vol.34 , pp. 277-282
    • Suomalainen, A.1
  • 8
    • 76549086505 scopus 로고    scopus 로고
    • A plasma signature of human mitochondrial disease revealed through metabolic profiling of spent media from cultured muscle cells
    • Shaham O, Slate NG, Goldberger O, et al. A plasma signature of human mitochondrial disease revealed through metabolic profiling of spent media from cultured muscle cells. Proc Natl Acad Sci USA 2010, 107:1571-1575.
    • (2010) Proc Natl Acad Sci USA , vol.107 , pp. 1571-1575
    • Shaham, O.1    Slate, N.G.2    Goldberger, O.3
  • 9
    • 70249133648 scopus 로고    scopus 로고
    • Development and implementation of standardized respiratory chain spectrophotometric assays for clinical diagnosis
    • Medja F, Allouche S, Frachon P, et al. Development and implementation of standardized respiratory chain spectrophotometric assays for clinical diagnosis. Mitochondrion 2009, 9:331-339.
    • (2009) Mitochondrion , vol.9 , pp. 331-339
    • Medja, F.1    Allouche, S.2    Frachon, P.3
  • 11
    • 34249686631 scopus 로고    scopus 로고
    • Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21
    • Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab 2007, 5:415-425.
    • (2007) Cell Metab , vol.5 , pp. 415-425
    • Inagaki, T.1    Dutchak, P.2    Zhao, G.3
  • 12
    • 34249711964 scopus 로고    scopus 로고
    • Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states
    • Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007, 5:426-437.
    • (2007) Cell Metab , vol.5 , pp. 426-437
    • Badman, M.K.1    Pissios, P.2    Kennedy, A.R.3    Koukos, G.4    Flier, J.S.5    Maratos-Flier, E.6
  • 13
    • 77957743736 scopus 로고    scopus 로고
    • Mitochondrial myopathy induces a starvation-like response
    • Tyynismaa H, Carroll CJ, Raimundo N, et al. Mitochondrial myopathy induces a starvation-like response. Hum Mol Genet 2010, 19:3948-3958.
    • (2010) Hum Mol Genet , vol.19 , pp. 3948-3958
    • Tyynismaa, H.1    Carroll, C.J.2    Raimundo, N.3
  • 14
    • 77957359658 scopus 로고    scopus 로고
    • Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride
    • Li H, Fang Q, Gao F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 2010, 53:934-940.
    • (2010) J Hepatol , vol.53 , pp. 934-940
    • Li, H.1    Fang, Q.2    Gao, F.3
  • 15
    • 63849189712 scopus 로고    scopus 로고
    • Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity
    • Mraz M, Bartlova M, Lacinova Z, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 2009, 71:369-375.
    • (2009) Clin Endocrinol (Oxf) , vol.71 , pp. 369-375
    • Mraz, M.1    Bartlova, M.2    Lacinova, Z.3
  • 16
    • 0019559193 scopus 로고
    • Selection and interpretation of diagnostic tests and procedures. Principles and applications
    • Griner PF, Mayewski RJ, Mushlin AI, Greenland P Selection and interpretation of diagnostic tests and procedures. Principles and applications. Ann Intern Med 1981, 94:557-592.
    • (1981) Ann Intern Med , vol.94 , pp. 557-592
    • Griner, P.F.1    Mayewski, R.J.2    Mushlin, A.I.3    Greenland, P.4
  • 17
    • 48349146527 scopus 로고    scopus 로고
    • Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans
    • Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008, 57:1246-1253.
    • (2008) Diabetes , vol.57 , pp. 1246-1253
    • Zhang, X.1    Yeung, D.C.2    Karpisek, M.3
  • 18
    • 66749106885 scopus 로고    scopus 로고
    • Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects
    • Li H, Bao Y, Xy A, et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 2009, 94:2151-2156.
    • (2009) J Clin Endocrinol Metab , vol.94 , pp. 2151-2156
    • Li, H.1    Bao, Y.2    Xy, A.3
  • 19
    • 77956276954 scopus 로고    scopus 로고
    • Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels
    • Cuevas-Ramos D, Almeda-Valdes P, Gomez-Perez FJ, et al. Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels. Eur J Endocrinol 2010, 163:469-477.
    • (2010) Eur J Endocrinol , vol.163 , pp. 469-477
    • Cuevas-Ramos, D.1    Almeda-Valdes, P.2    Gomez-Perez, F.J.3
  • 20
    • 77956519052 scopus 로고    scopus 로고
    • Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease
    • Yilmaz Y, Eren F, Yonal O, et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest 2010, 40:887-892.
    • (2010) Eur J Clin Invest , vol.40 , pp. 887-892
    • Yilmaz, Y.1    Eren, F.2    Yonal, O.3
  • 21
    • 78650850911 scopus 로고    scopus 로고
    • Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profiles
    • Lin Z, Wu Z, Yin X, et al. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profiles. PLoS One 2010, 5:e15534.
    • (2010) PLoS One , vol.5
    • Lin, Z.1    Wu, Z.2    Yin, X.3
  • 25
    • 47949111205 scopus 로고    scopus 로고
    • Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor γ and altered metabolic states
    • Muise ES, Azzolina B, Kuo DW, et al. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor γ and altered metabolic states. Mol Pharmacol 2008, 74:403-412.
    • (2008) Mol Pharmacol , vol.74 , pp. 403-412
    • Muise, E.S.1    Azzolina, B.2    Kuo, D.W.3
  • 26
    • 48349127924 scopus 로고    scopus 로고
    • The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man
    • Galman C, Lundasen T, Kharitonenkov A, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 2008, 8:169-174.
    • (2008) Cell Metab , vol.8 , pp. 169-174
    • Galman, C.1    Lundasen, T.2    Kharitonenkov, A.3
  • 27
    • 51649118899 scopus 로고    scopus 로고
    • Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa
    • Dostalova I, Kavalkova P, Haluzikova D, et al. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 2008, 93:3627-3632.
    • (2008) J Clin Endocrinol Metab , vol.93 , pp. 3627-3632
    • Dostalova, I.1    Kavalkova, P.2    Haluzikova, D.3
  • 28
    • 77955474305 scopus 로고    scopus 로고
    • Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease
    • Dushay J, Chui PC, Gopalakrishnan GS, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010, 139:456-463.
    • (2010) Gastroenterology , vol.139 , pp. 456-463
    • Dushay, J.1    Chui, P.C.2    Gopalakrishnan, G.S.3
  • 29
    • 78349310229 scopus 로고    scopus 로고
    • Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients
    • Domingo P, Gallego-Escuredo JM, Domingo JC, et al. Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients. AIDS 2010, 24:2629-2637.
    • (2010) AIDS , vol.24 , pp. 2629-2637
    • Domingo, P.1    Gallego-Escuredo, J.M.2    Domingo, J.C.3
  • 30
    • 79951713560 scopus 로고    scopus 로고
    • Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins
    • Tyynismaa H, Raivio T, Hakkarainen A, et al. Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. J Clin Endocrinol Metab 2011, 96:E351-E355.
    • (2011) J Clin Endocrinol Metab , vol.96
    • Tyynismaa, H.1    Raivio, T.2    Hakkarainen, A.3
  • 31
    • 23944508509 scopus 로고    scopus 로고
    • Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin
    • Hakonen AH, Heiskanen S, Juvonen V, et al. Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. Am J Hum Genet 2005, 77:430-441.
    • (2005) Am J Hum Genet , vol.77 , pp. 430-441
    • Hakonen, A.H.1    Heiskanen, S.2    Juvonen, V.3
  • 32
    • 74049124412 scopus 로고    scopus 로고
    • Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease
    • Ju JS, Fuentealba RA, Miller SE, et al. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J Cell Biol 2009, 187:875-888.
    • (2009) J Cell Biol , vol.187 , pp. 875-888
    • Ju, J.S.1    Fuentealba, R.A.2    Miller, S.E.3
  • 33
    • 1842483843 scopus 로고    scopus 로고
    • Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein
    • Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004, 36:377-381.
    • (2004) Nat Genet , vol.36 , pp. 377-381
    • Watts, G.D.1    Wymer, J.2    Kovach, M.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.